EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody

Courtney Moc Willeford iD, Krithika Shetty iD, Douglas Sheridan iD, Frank Engler iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13250 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Courtney Moc Willeford und 3 weiteren Autor:innen. Beteiligte Einrichtung: Certara USA, Radnor, Pennsylvania, USA. Hauptthemen laut MEDLINE: Models, Biological, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rallybio IPA, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RLYB212 is a human monoclonal anti‐human platelet antigen (HPA)‐1a immunoglobulin gamma 1 in clinical development as a subcutaneous injection for the prevention of maternal alloimmunization to fetal HPA‐1a leading to fetal and neonatal alloimmune thrombocytopenia (FNAIT). This analysis developed a target‐mediated drug disposition (TMDD) model to simultaneously characterize RLYB212 pharmacokinetics (PK) and HPA‐1a‐positive platelet dynamics in HPA‐1b/b (HPA‐1a‐negative) volunteers. The model was then used to perform simulations to inform a dosing regimen in a phase II clinical study in pregnant women, where simulations accounted for physiological changes throughout pregnancy. Allometric scaling (0.75) for clearance and intercompartment transfer rate and volume (1) was included in the base model to account for variations in body weight. A 0.06 mg RLYB212 dose with a loading dose of 0.12 mg was identified as the optimal dosing regimen of RLYB212, which maintained exposures below the target upper boundary of ~10 ng/mL throughout pregnancy. This work presents an application of the TMDD model that advances the quantitative clinical pharmacology toolkit to understand monoclonal antibody PK in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalAntibodies, MonoclonalHumansFemalePregnancyComputer SimulationRecombinant ProteinsAdultAntigens, Human PlateletDose-Response Relationship, DrugThrombocytopenia, Neonatal AlloimmuneYoung Adult

Substanzen

Antibodies, MonoclonalRecombinant ProteinsAntigens, Human Platelet

Autor:innen und Institutionen

  • Certara USA, Radnor, Pennsylvania, USA.
  • Rallybio, New Haven, Connecticut, USA.

ORCID-Profile: Courtney Moc Willeford, Krithika Shetty, Douglas Sheridan, Frank Engler

Förderung

  • Rallybio IPA, LLC

Zitieren

APA

Moc Willeford, C., Shetty, K., Sheridan, D., & Engler, F. (2024). Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13250

Vancouver

Moc Willeford C, Shetty K, Sheridan D, Engler F. Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13250

BibTeX
@article{MocWilleford2024,
  author = {Moc Willeford, Courtney and Shetty, Krithika and Sheridan, Douglas and Engler, Frank},
  title = {Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13250}
}
Kostenlos starten →